meet our advisors, women's health, obstetrics, gynecology, infertility, pregnancy, hysterectomy, fibroids, and more

 

Print this page
OBGYN.net Advertisement
Editorial Advisor Serge Rozenberg, MD - Belgium

OBGYN.net Editorial Advisor
Osteoporosis


Serge Rozenberg, MD - Belgium

 

Menopause & Osteoporosis unit
Department of OB-GYN
St Peter University Hospital
Hoog Str 290
1000 Brussels
Tel : 322-535.34.08
Fax : 322-537.59.26

Born on March 8th 1957 in Antwerp.
Nationality : Belgian.
Married with three children

Studies En Titels
Free University of Brussels (Vrije Universiteit Brussel) 1976-1982
School of Medicine, MD Graduated in 1982 Magnum cum laude.

Prespecialisation 1982 : Gynaecology and Obstetrics
Summa Cum Laude: « luteinized unruptured follicle syndrome ».

Thesis ( Aggregaatsthesis to compare with PhD) 1994 : « bone mineral status and postmenopausal osteoporosis prevention »

Position:
Associate Head of Clinic (Adjunct kliniekhoofd) in the department of Gynaecology and Obstetrics of the University Hospital St. Peter in Brussels,Free University of Brussels, responsible for the Unit of Menopause and Osteoporosis.

Member of Societies
The Endocrine society, The American association for bone and mineral research, The International Conferences on Calcium Regulating Hormones, The International menopause society.
Past-Treasurer of The Belgian Bone Club, Current President of the Belgian Menopause Society
Member of the advisory board "Women's Health after Menopause". Member of the editorial review board of "Endocrinological gynaecology and menopause" (Spain). Referee for Maturitas
Editor of The « International Journal of Ferility and Menopausal Studies ».
Member of the editorial review board of « Climacteric, Menopause Reviews, Endocrinological gynaecology and menopause ».

Publications

Chapters in books

  1. Apport de l'étude des primates non hominiens dans la compréhension du mécanisme des perturbations de l'ovulation.
  2. C. Robyn & S. Rozenberg. In : Progrès en Gynécologie, vol.1, Inductions et stimulations de l'ovulation, Buvat J., ed. Editions Doin, France.

Peer review journals

  1. La prolactine et le sein après la ménopause. C. Robyn and S. Rozenberg. Sein et Ménopause. Hormones, reproduction, métabolisme, 1985;6:32-39.
  2. Hyperprolactinemia and osteoporosis. S. Rozenberg et C. Robyn. IRCS Med Sci, 1986;14:413-414.
  3. Biological profiles of patients with discordances between cortical and trabecular bone mineral contents. S. Rozenberg, H. Ham, D. Bosson, A.Peretz, C. Robyn. J Med Sci Res, 1987;15:1097-1099.
  4. Serum levels of gonadotropins and steroid hormones in female patients after the menopause and late in life. S. Rozenberg, D. Bosson, A. Peretz, C. Robyn. Maturitas, 1988, 10: 215-224.
  5. Osteocalcin and bone mineral content in rheumatoid arthritis. A. Peretz, J.P. Praet, D. Bosson, S. Rozenberg, J.P. Famaey, & P. Bourdoux. Clinical Rheumatology, 1988;8:42-48.
  6. Serum osteocalcin in the assessment of corticosteroid-induced osteoporosis. Effect of long and short term corticosteroid treatment. A. Peretz, J.P. Praet, D. Bosson, S. Rozenberg & P. Bourdoux. Journal of Rheumatology, 1989;16:363-367.
  7. Ovarian stimulation for IVF is associated with a decrease in serum osteocalcin levels. S. Rozenberg, P. Bourdoux, T. Bril, A. Peretz, B. Lejeune, F. Leroy, C. Robyn. Medical Science Research, 1989;17:591-592.
  8. Relations between age, steroid hormones and bone mineral contents in women. S. Rozenberg, H. Ham, D. Bosson, A. Peretz, C. Robyn. Maturitas, 1990;12:137-143.
  9. Letter to the editor, S.Rozenberg, H.Ham, A. Peretz. Journal of Bone and Mineral Research, 1990;12:1273-1274.
  10. Choice of parameter for expressing bone mineralization. S. Rozenberg, H. Ham, A. Peretz, A. Caufriez, D. Bosson, C. Robyn. Nuclear Medecine Communication 1991;12:189-195.
  11. Serum androgens during illness. S.Rozenberg, H.Ham, A. Peretz. Clinical Endocrinology 1991;35:373-374 (letter).
  12. Time related bias in longitudinal studies using dual photon absorptiometry. S. Rozenberg, J. Vandromme, A. Peretz, J.P. Praet, C. Robyn, H. Ham. Journal of Endocrinological Investigation (1992) 15, 835-837.
  13. Risk of osteoporosis in men with chronic bronchitis. JP.Praet, A.Peretz, S.Rozenberg, JP.Famay, P.Bourdoux. Osteoporosis Int (1992) 2:257-261.
  14. Bone mineral density at the vertebral site by dual photon absorptiometry and dual enery X-ray absorptiometry: a problem of accuracy. S. Rozenberg, J. Vandromme, A. Peretz, J.P. Praet, H. Ham. Nuclear Medicine Communication 1993, 14, 189-191.
  15. Decrease of bone mineral density during estrogen substitution therapy. S. Rozenberg, R. Gevers, A. Peretz, J. Vandromme, A. Van Onderbergen, C. Robyn, H. Ham. Maturitas 1993; 17:205-210.
  16. Bone mineral content of women with uterine fibromyomas. S.Rozenberg, A. Perets, H. Ham, C. Robyn, M. Degueldre. Int J Fertil 39 (2):77-80, 1994.
  17. Estrogen replacement therapy and cardiovascular risk: a place for a hemodynamic etiology? S. Rozenberg, I. Liebens, J. Vandromme, A. Hotimsky, M. Vanrijsselbergh. Int J Fertil and Menopausal Studies 39:36-42, 1994.
  18. Osteoporosis prevention with sex hormone replacement therapy. S.Rozenberg, M.Kroll, J.Vandromme, A.Pastijn, M.Degueldre. Int J Fertil and Menopausal studies 1994 ; 39 (5): 262-271.(Review)
  19. Increased serum immunoreactive calcitonin in patients with acute diseases. A. Peretz, P. Bourdoux, JJ. Body, JP. Praet, S. Rozenberg, JP. Famaey Journal of Tumor Markers Oncology 1994, 9 (4) : 39-45.
  20. Precision and accuracy of in-vivo bone mineral measurements in rats using Dual-Energy X-ray Absorptiometry. S.Rozenberg, J.Vandromme, J.Neve, A.Aguillera, A.Muregancuro, A.Peretz, J.Kinthaert, H.Ham Osteoporosis Int 1995, 5:47-53.
  21. Clinical significance of regional heterogeneity in vertebral mineral density. S. Rozenberg, J. Vandromme, A. Alvaro, A. Peretz, H. Ham. Maturitas 1995, 21:147-151.
  22. Clinical usefulness of bone mineral measurements in the prevention of postmenopausal osteoporosis. S.Rozenberg, J.Vandromme, M.Kroll, A.Peretz, JP.Praet, H.Ham. Int J Fertil and Menopausal studies 1995, 40,1: 12-24 (Review).
  23. Compliance of hormone replacement therapy. S.Rozenberg, J.Vandromme, M.Kroll, A.Peretz, JP.Praet, H.Ham. Int J Fertil and Menopausal studies 1995,40,1 :23-32 (Review).
  24. Osteoporosis prevention with sex hormone replacement therapy. S.Rozenberg, M.Kroll, A.Pastijn, J.Vandromme. Clin Rhumatology 1995, 14, (Review).
  25. Hormone replacement therapy for osteoporosis prevention: from medical science to clinical practice. S.Rozenberg, M.Kroll, J.Vandromme Journal Fertil and Menopausal studies Int J Fertil and Menopausal studies, 1995 ;40 (3) :154-160 (Review).
  26. Observance au traitement hormonal de substitution. S.Rozenberg, J.Vandromme, M.Kroll, P.Twagirayezu et J.Vyankandondera Rev Med Brux 1995 ; (156): 295-298 (Review).
  27. Effect of bone density evaluation on hormone replacement therapy prescription. S.Rozenberg, M.Kroll, J.Vandromme, M. Paesmans, H. Ham. Maturitas 1996, 24 (1) :57-62.
  28. Principal cancers of women : breast, lung and colorectal. S.Rozenberg, F Liebens, M.Kroll, J.Vandromme Int Journal Fertil and Menopausal studies 1996,41 (2) :166-171 (Review).
  29. Decision factors influencing hormone substution therapy prescription. S.Rozenberg, M.Kroll, J.Vandromme Br J Obstet Gynaecol 1996, 103 (13) :92-98 (Review).
  30. Cyclical pamidronate infusion in osteoporosis: effects on bone metabolsim and bone mineral density. A. Peretz, JJ Body, JC Dumon, S. Rozenberg, A Hotimski, JP Praet, M Moris, H. Ham, P Bergmann. Maturitas 1996, 25(1) :69-75.
  31. The Brittle Bone : How to Save Women From Osteoporosis. S. Rozenberg, J.Vandromme, M.Kroll, P.Twagirayezu et J.Vyankandondera, K.Claus Int Journal Fertil and Menopausal studies 1997 ;42 (2) :101-106 (Review).
  32. Factors influencing the prescription of hormone replacement therapy. S. Rozenberg, M. Kroll, J. Vandromme, M. Paesmans, A. Lefever, H. Ham Obstetrics and Gynecology 1997 ;90 :387-91.
  33. Comparison of continuous and sequential trandermal progesteron with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen : vasomotor symptoms, bleeding pattern and serum lipids. S. Rozenberg , Olavi Ylikorkala on behalf of the International group of investigators. International Journal of Fertility and women’s medicine 1997, 42(2) :376-387.
  34. Effect of estrogen replacement therapy with or without concomitant non steroidal anti-inflammatory drugs on pulsatility and resistance index of uterine arteries in healthy postmenopausal women. S. Rozenberg, P. Twagirayezu, J. Vyankadondera, A. Hotimsky, M. Van Rysselberge. Int Journal Fertil and Menopausal studies 1997, 42 (4) 240-244.
  35. Prevention and treatment of postmenopausal osteoporosis. National consensus of the "Belgian Bone Club", November 1996. Kaufman JM, Devogelaer JP, Raeman F, Rozenberg S, Body JJ, Westhovens R, Reginster JY. Clin Rheumatol 1997 Jun;16(4):343-345.
  36. Facilitating Patient-Specific Decisions Regarding Hormone Replacement Therapy S.Rozenberg, J. Vandromme, H.Ham JAMA 1997 ;278:475 (lettre)
  37. Educating patients about the benefits and drawbacks of hormone replacement therapy : a practical guide. S. Rozenberg Drugs and Aging (in press Review).
  38. Oral calcium loading test: comparison of 2 salts in young and elderly postmenopausal women JP. Praet, A. Peretz, S. Rozenberg. Journal of Endocrinological Investigation (in press).
  39. Hormone replacement therapy : Thirty minutes information valid for for thirty years. S.Rozenberg, J. Barudy Vasquez, M. Kroll, J. Vandromme, Gynecol Endocrinol 1998 (suppl 2) ;12 :1-8 (Review)

Proceedings

  1. Les effets secondaires endocriniens des neuroleptiques. C. Robyn and S. Rozenberg. Semaines des Hôpitaux de Paris, 1985;19:1358-1364.
  2. Advances in Physiology of Human Lactation. C. Robyn, N.I. Brandts, S. Rozenberg, S. Meuris. In Endocrinology of the breast, Angeli A. and Doghiotti (eds), Annals New York Academy of Sciences, 1986;464:66-74.
  3. Physiopathology of prolactin. C. Robyn & S. Rozenberg. Annual meeting of the Greek Society of Endocrinology on Prolactin, Sterility and Benign Breast disease (Athenes April 5 1986).
  4. La reproductibilité des mesures du contenu osseux (BMC) et de la densité osseuse (BMD) par absorptiométrie biphotonique (A.B.). S. Rozenberg, A. Peretz, C. Robyn, H. Ham. Journal de Biophysique et de Biomécanique 1987;11:167-170.
  5. Influence de la taille sur le métabolisme osseux. Journal de Biophysique et Biomécanique. S. Rozenberg, H. Ham, A. Peretz, T. Bril & C. Robyn, A. Peretz, T. Bril & C. Robyn.
  6. The validity of bone mineral measurements at the vertebral site is age related. S. Rozenberg, A. Peretz, A. Caufriez, C. Robyn, H. Ham. In: Osteoporosis, Christiansen C, Johansen JS, Rijs BJ (eds), 1987, Norhaven A/S, Viborg, Denmark, pp. 72-73.
  7. Controversy in diagnosis and treatment of infertility due to hormonal impairment. C. Robyn, S. Rozenberg, S. Meuris In Controversies in reproductive Medecine ed. H.S. Jacobs, editions the Partenon, 1989, pp. 13-46.
  8. Sex and adrenal steroids in female- and outpatients after the age of 40. S. Rozenberg, H. Ham, D. Bosson, A. Peretz, C. Robyn. Annales of New York Academy of Science, 1990;592:466-468.
  9. Serum levels of DHEAS in the perimenopause. S. Rozenberg, H. Ham, A. Caufriez, A. Peretz, A. Brans, D. Bosson, C. Robyn. Annales of New York Academy of Science, 1990;592:469-471.
  10. Evolution of osteocalcin , alkaline phosphatase and parathyroid hormone after parathyroidectomy in patients on chronic maintenance hemodialysis. A. Peretz, M. Dhaene, S. Rozenberg, P. Bourdoux, JP Famaey. In Osteoporosis 1990 eds C.Christiansen & K.Overgaard, Copenhagen, Denmark, vol 2, pp 739-740.
  11. Oral calcium loading test: comparison of 2 salts in pre- and postmenopausal women JP. Praet, A. Peretz, S. Rozenberg, JP Famaey, P. Bourdoux. In Osteoporosis 1990 eds C.Christiansen & K.Overgaard, Copenhagen, Denmark, vol 2, pp. 1212-1213.
  12. Male Chronic Bronchitis patients and risk for osteoporosis Praet, A. Peretz, S. Rozenberg, JP Famaey, P. Bourdoux. In Osteoporosis 1990 eds C.Christiansen & K.Overgaard, Copenhagen, Denmark, vol 3, pp. 1754-1755.
  13. Bone mineral content of women with breast cancer. S. Rozenberg, F. Liebens, H. Ham, M. Degueldre, A. Peretz, N. Cluydts, C. Robyn. In Osteoporosis 1990 eds C.Christiansen & K.Overgaard, Copenhagen, Denmark, vol 1, pp 208.
  14. Monitoring and follow-up of hormonal replacement therapy. S.Rozenberg In Menopause, present and future eds Satntiago Palacios, Proceedings of the II Congress of the European menopause society, Madrid 29-31 October 1992 pp 45-50.
  15. Estrogen replacement therapy and cardiovascular disease: Mechanism of Action: Hemodynamics. S.Rozenberg, I. Liebens, J. Vandromme, A. Hotimsky, M. Van Rijsselberge. Proceedings of International Symposium on Women's Health in Menopause: Behaviour, Cancer, Cardiovascular Disease, Hormone Replacement Therapy. (eds PG. Crosignani, R.Paoletti, PM. Sarrel, NK.Wenger, M.Meschia, M.Soma) Kluwer Academic Publishers 1994.
  16. Overwegingen om een hormoon subtitutie therapie voor te schrijven. S.Rozenberg, A. Pastijn. in Gynaecologie, Preventie, Diagnostiek en Therapie Anno 1995, Proceedings van het congres De Doelen, Rotterdam, Nederland 8-10 Februari 1995.


Articles

  1. Trabecular and cortical bone mineral contents : their relations with biological and anthropometric factors. S. Rozenberg, H. Ham, T. Bril, A. Caufriez, A. Peretz & C. Robyn. J Nucl Med, 1987;28:686 (abstract).
  2. Biological profiles of patients with discordance between cortical and trabecular bone mineral contents. S. Rozenberg, H. Ham, D. Bosson, A. Peretz & C. Robyn. Endocrinology, 1987;120:241 (abstract).
  3. Relations between age, steroid hormones (estrogens and androgens) and bone mineral contents (trabecular and cortical) in women. S. Rozenberg, H. Ham, A. Peretz, D. Bosson, C. Robyn. Endocrinology, 1988;122:139 (abstract).
  4. Different influences on trabecular and cortical bone mineral content? S. Rozenberg, A. Peretz, H. Ham, T. Bril, J.P. Praet & C. Robyn. Acta Clinica Belgica, 1988;43(12):49 (abstract).
  5. Place of osteocalcin in the assessment of bone turnover. A. Peretz, J.P. Praet, D. Bosson, S. Rozenberg & P. Bourdoux. Acta Clinica Belgica, 1988;43(12):116 (abstract).
  6. Effet de l'administation chronique et aigue de cortico‹des sur les valeurs d'ostéocalcine. A. Peretz, J.P. Praet, D. Bosson, S. Rozenberg & P. Bourdoux. Annales d'Endocrinologie 1988;49(6):127 (abstract).
  7. Les effets de la Gestrinone sur les leiomyomes. M. Degueldre, F. Liebens, S. Rozenberg, C. Bourgain, E. von Lennep & C. Robyn. Annales d'Endocrinologie 1988;49(6):112 (abstract).
  8. Relation entre la taille et le contenu osseux. S. Rozenberg, H. Ham, A. Peretz, D. Bosson & C. Robyn. Annales d'Endocrinologie 1988;49(6):126 (abstract).
  9. What influence bone mineral content? S. Rozenberg, A. Peretz, H. Ham, T. Bril, A. caufriez & C. Robyn. Journal of Bone and Mineral Research 1988;3:88 (abstract).
  10. Assessment of bone turnover by osteocalcin. A. Peretz, J.P. Praet, S. Rozenberg & P. Bourdoux. Journal of Bone and Mineral Research 1988;3:179 (abstract).
  11. Increased calcitonin levels in ill patients. A. Peretz, G. Mueller, J.P. Praet, S. Rozenberg, D. Bosson, P. Bourdoux. Journal of Bone and Mineral Research, 1989;4:306 (abstract).
  12. Relationships between serum levels of sex steroids, vitamin D and prolactin in women after adjustment for age. Proceeding of The Endocrine Society, 71th Annual Meeting, Seattle, Washington, June 21-24, 1989. S. Rozenberg, T. Bril, A. Peretz, C. Robyn (abstract).
  13. Should reference values of BMC be reassessed annually ? S.Rozenberg, H.Ham, A.Peretz, JP. Praet, C.Robyn. Journal of Bone and Mineral Research, 1990;5:242 (abstract)
  14. The relative importance of anthropometric factors on bone mineral content and density. S.Rozenberg, H.Ham, A.Peretz, A.Caufriez, JP.Praet, C.Robyn. Journal of nuclear medecine 1990;31:81 (abstract).
  15. Decrease of bone mineral density during estrogen substitution therapy. S.Rozenberg, R.Gevers, A.Peretz, J.Vandromme, C.Robyn, H.Ham. Bone and Mineral 1992;17(suppl):A288 (abstract).
  16. Effect of acute illness on the neuroendocrine secretion of calcitonin. A.Peretz, P.Bourdoux, JJ.Body, JP.Praet, S.Rozenberg, JP.FAmey. Bone and Mineral 1992;17 (suppl):A 489 (abstract).
  17. Effect of inhaled glucocorticoid on osteoblastic function. A.Peretz, JP.Praet, S.Rozenberg, P.Bourdoux, JP.Famay. XIth ICCRH Conference, Florence, Italy 24-29 april, 1992 (abstract).
  18. In vivo precision of whole body- and localized bone mineral content and density in rats as measured by DXA. S.Rozenberg, M.Kroll, V.Badot, M.Ghierche, JC.Bier, J.Vandromme. Bone and Mineral 1994; 9 (suppl): C372 (abstract).
  19. Effect of Bone Density Evaluation on Hormone Replacement Therapy prescription. S.Rozenberg, M.Kroll, J.Vandromme, H. Ham, M. Paesmans. Journal of Bone Mineral Research 10:(suppl 1), 1995 (Abstract)
  20. Physicians attitude towards hormone replacement therapy prescription for postmenopausal osteoporosis prevention. S.Rozenberg, M.Kroll, J.Vandromme, H.Ham, A. Lefever, C. Riera, M.Paesmans Journal of Bone Mineral Research, 1996,11(suppl 1) (Abstract) .
  21. Bone Mineral Density and risk of breast cancer in women. S.Rozenberg, F. Liebens, M. Kroll, J. vandromme, H. Ham. Acta Obstetrica et Gynecologica Scandinavica 1997, 76 (167) p48.14 (Abstract).
  22. Are there still non-osteoporotic subjects in this room of women ? H. Ham, S. Rozenberg, Acta Obstetrica et Gynecologica Scandinavica 1997, 76 (167) p63.33 (Abstract).
  23. Prescription of oesteoporosis medication in the postmenopause. A. Lefever, S. Rozenberg, M. Kroll, J. Vandromme, M. Paesmans, H. Ham Acta Obstetrica et Gynecologica Scandinavica 1997, 76 (167) p63.34 (Abstract).
  24. Factors influencing the prescription of HRT A. Lefever, S. Rozenberg, M. Kroll, J. Vandromme, M. Paesmans, H. Ham Acta Obstetrica et Gynecologica Scandinavica 1997, 76 (167) p86.2 (Abstract).
  25. Prescription and continuation rate of HRT in women with myoma after the menopause. K. Claus, S. Rozenberg, M. Kroll, J. Vandromme, M. Paesmans, M. Degueldre Acta Obstetrica et Gynecologica Scandinavica 1997, 76 (167) p86.64 (Abstract).
  26. Evaluation of continuous and sequential transdermal progestogen added to transdermal estrogen in postmenopausal women : .vaomotor symptoms, bleeding patterns and serum lipids. S. Rozenberg Acta Obstetrica et Gynecologica Scandinavica 1997, 76 (167) SS82.2 (Abstract).
  27. Estradiol effect on uterine arteries doppler in postmenopausal women : a prostaglandin mediated mechanism? P. Twagirayezu, S. Rozenberg, , J.Vyankakoundera, A. Hotimsky, M. Van Rijsselberge. Acta Obstetrica et Gynecologica Scandinavica 1997, 76 (167) (Abstract).
  28. Factors influencing the prescription of HRT A. Lefever, S. Rozenberg, M. Kroll, J. Vandromme, M. Paesmans, H. Ham Journal of Bone Mineral Research, 1996,11(suppl 1) (Abstract) .

Local publications

  1. La ménopause. C. Robyn and S. Rozenberg. Journées d'enseignement post-universitaire de l'AMUB, Bruxelles, 22.09.85, pp. 285-291.
  2. Hormones et ostéoporose postménopausique. S. Rozenberg. Journéesd'enseignement postuniversitaire de l'A.M.U.B., 23.09.1987, pp. 42-45.
  3. Anthropometric factors in the prevention of osteoporosis. S. Rozenberg, H.Ham, A. Peretz, J.P. Praet, C. Robyn. Belgisch Archief, Sociale Geneeskunde, Hygiène, Arbeidsgeneeskunde, Gerechtelijke Geneeskunde, 1989.
  4. Hyperprolactinemie : biochemische, biologische, fysiopathologische en therapeutische aspecten. C. Robyn, S. Rozenberg, S. Meuris. Tijdschrift voor fertiliteitsonderzoek 1989.
  5. Les bouffées de chaleur. S.Rozenberg, C.Robyn. Impact médecin 1990;54:4-9.
  6. Quel traitement peut-on offrir à des patients qui souffrent d'une ostéoporose symptomatique ? S. Rozenberg Ostéoporose Info 1990;6.
  7. Rapport du 6ème Congrès de la Ménopause. S.Rozenberg. Tempo Medical 1990 supplément.
  8. Algemene principes van de hormoonsubstitutietherapie. S. Rozenberg. In: De menopause, Medical Science Liaison, 1992 p107-113.
  9. Facteurs de risque de l’ostéoporose. S.Rozenberg. Tempo Medical 1992.
  10. Ostéoporose chez une femme de 35 ans. S.Rozenberg. Tempo Medical 1992.
  11. Contrôle de l’endomètre et rôle des progestagènes. S.Rozenberg. Medi-Sphère 1992, 16, 13-15.
  12. Abnormale bloedingen tijdens de hormoonsubstitutie behandeling en bijzondere voorzorgen. S.Rozenberg In : Praktische gids voor de menopauze 1992.
  13. Hormoonsubstitutie behandeling na de menopauze. S.Rozenberg. in Bijscholing voor apothekers: Gynaecologische problemen en sexuele overdraagbare ziekten. faculteit geneeskunde en farmacie VUB 1992-1993. Coordinators: Profs JJ Amy, V. Rogiers. p 12-17.
  14. Place des hormones stéroïdes sexuelles dans la prévention et le traitement de l’ostéoporose. S.Rozenberg. Dialogue Novembre 1993.
  15. Nouveautés en ostéoporose ? S.Rozenberg, J. Vandromme. Medi-Sphère Gynécologie septembre 1993.
  16. Ovarian hyperstimulation syndrome: a possible gynaecological emergency. A. Delvigne, A. Pastijn, S. Rozenberg. Gynaecology Snapshot, 1994,2,3:12-15.
  17. Gyn obs 8/ 1995 traitement hormonale de substitution dans les cas de pathologies cardiaques I. Liebens, S. Rozenberg.
  18. Effet du traitement hormonale de substitution sur le squelette. Le Monde médical de la femme S. Rozenberg, J. Vandromme, A. Pastijn, M Kroll 5/1995.
  19. Troubles hormonaux, perte osseuse à la périmenopause. Le Monde médical de la femme. J. Vandromme, S. Rozenberg 8/1995.
  20. Rapport de la Réunion de Consensus sur Ostéoporose « Montreux European Consensus Meeting September 8-10, 1995 », Gunaikeia 1996.
  21. Ostéoporose et qualité de vie. Le Monde médical de la femme J. Vandromme, S. Rozenberg 1996.
  22. Diagnostiek van osteoporose JP Devogelaer, JY Reginster, F. Raeman, R. Westhovens, S. Rozenberg, JJ Body, JM Kaufman Medipractice 1997
  23. La Contraception à la périménopause. Gunaïkeia 1997, 3(2) :77.